OKYO Pharma Limited (NASDAQ:OKYO – Free Report) – Analysts at HC Wainwright reduced their Q2 2025 earnings per share (EPS) estimates for OKYO Pharma in a report released on Wednesday, October 16th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.11) per share for the quarter, down from their prior forecast of ($0.09). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for OKYO Pharma’s current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for OKYO Pharma’s Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.40) EPS.
OKYO Pharma Stock Up 1.0 %
NASDAQ:OKYO opened at $1.02 on Monday. OKYO Pharma has a fifty-two week low of $0.81 and a fifty-two week high of $2.12. The firm’s fifty day simple moving average is $1.04 and its 200-day simple moving average is $1.25.
OKYO Pharma Company Profile
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
Recommended Stories
- Five stocks we like better than OKYO Pharma
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Is Spotify Stock Poised to Soar? Options Traders Think So
- How to Evaluate a Stock Before BuyingÂ
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- What is an Earnings Surprise?
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
